Canada markets close in 3 hours 24 minutes

Grifols, S.A. (GIFLF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
Add to watchlist
10.68+0.80 (+8.10%)
As of 09:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close9.88
Open10.68
Bid0.00 x 0
Ask0.00 x 0
Day's Range10.68 - 10.68
52 Week Range7.46 - 15.80
Volume1,286
Avg. Volume1,452
Market Cap6.129B
Beta (5Y Monthly)0.67
PE Ratio (TTM)106.80
EPS (TTM)0.10
Earnings DateMay 14, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 03, 2021
1y Target EstN/A
  • Bloomberg

    Short Seller Gains on Grifols Bet That Tripped Elliott Spinout

    (Bloomberg) -- A well-publicized short bet by General Industrial Partners on Spanish company Grifols SA helped the hedge fund earn double-digit gains while bullish wagers on the same stock caused losses to former Elliott Management trader Franck Tuil.Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio Closings‘Seriously Underwater’ Home Mortgages Tick Up Across the USAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackMarjorie Taylor Greene Finally Got Wha

  • PR Newswire

    Grifols 2023 Annual Report on Form 20-F filed with the SEC

    Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").

  • GlobeNewswire

    Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

    The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi